You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
AstraZeneca
McKinsey
Harvard Business School

Last Updated: April 2, 2020

DrugPatentWatch Database Preview

Litigation Details for Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)

Docket   Start Trial Date Filed 2013-10-08
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS LABORATORIES UT INC.; INTELGENX TECHNOLOGIES CORP.; LTS LOHMANN THERAPY SYSTEMS CORP.; MONOSOL RX LLC; PAR PHARMACEUTICAL INC.; RB PHARMACEUTICALS LIMITED; RECKITT BENCKISER PHARMACEUTICALS INC.; WATSON LABORATORIES INC.
Patents 3,632,740; 3,996,934; 4,529,601; 4,615,697; 4,915,950; 5,023,082; 5,186,938; 5,234,957; 6,159,498; 6,264,981; 6,488,963; 7,579,019; 8,017,150; 8,475,832; 8,603,514
Attorneys Ashlea Raymond Pflug; Bennet J. Moskowitz; Cassandra A Adams; Dana Kathryn Severance; Daniel A. Ladow; Daniel Marcus Attaway; David A. Bilson; David L. Hecht; David P. Dalke; Douglas D. Salyers; Emily C. Melvin; Erica N. Andersen; Houda Morad; J. Magnus Essunger; James F. Hibey; James K. Lynch; Jeffrey B. Elikan; Jennifer Koh; John C. Phillips , Jr.; Katharine Lester Mowery; Mary W. Bourke; Megan C. Haney; Melinda K. Lackey; Michael K. Nutter; Michelle R. Ma; Peter E. Perkowski; Peter J. Slawniak; Rachel M. Hofstatter; Sharick Naqi; Stephanie L. Schonewald; Stephen R. Smerek; Steven J. Fineman; Timothy C. Bickham; Timothy P. Heaton
Link to Docket External link to docket
Small Molecule Drugs cited in Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.
Biologic Drugs cited in Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2015-06-26 296 construction of a single term of U.S. Patent No. 8,475,832 ("the '832 Patent"). The Court previously…claim construction of a single term of U.S. Patent No. 8,475,832 (see Opinion for further details). Signed…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification…TERM A. The '832 Patent Claim 1 of the '832 patent reads: A film dosage composition External link to document
2015-08-05 309 Regarding Watsons Infringement of U.S. Patent Nos. 8,475,832 and 8,603,514 filed by MonoSol Rx LLC, RB… 8 October 2013 1:13-cv-01674-RGA Patent None District Court, D. Delaware External link to document
2016-06-03 446 quot;the '514 patent"); and 8,017,150 (''the '150 patent"); Reckitt' s suits… Asserted Patents I. '832 Patent The '832 patent is directed…alleging infringement of U.S. Patent Nos. 8,475,832 (''the '832 patent"); 8,603,514 ("… the '150 and '514 patents and infringement of the '150 patent by Watson (D.I. 414, 415).…the validity of the '832 patent, infringement of the' 150 patent by Par, and infringement of External link to document
2014-08-04 80 near the glass transition,” Carbo 3,632,740 A 1/1972 Robinson et…active agent With no more than a 10% vari 3,632,740 A 1/1972 Robinson et al.…United States Patent Nos. 8,475,832 (“the ʼ832 patent”) and 8,017,150 (“the ʼ150 patent”), and 8,603,514…the ʼ150 patent, and Plaintiff RBP is an exclusive licensee of the ʼ150 patent. The ʼ150 patent, entitled…the ʼ514 patent, and Plaintiff RBP is an exclusive licensee of the ’514 patent. The ʼ514 patent, entitled External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Baxter
Colorcon
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.